Replies to post #429 on Fate Therapeutics Inc (FATE)

[NY1972]

Sounds like it is not part of novel H2CasMab-2 binder and 1XX CAR.
Selective: Uniquely exhibits robust and preferential targeting of HER2 on tumor cells and not
on normal cells, aided by novel H2CasMab-2 binder and TRAC-mediated 1XX CAR activity